BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; low-dose infigratinib, a treatment option for children living with hypochondroplasia, a skeletal dysplasia closely related to achondroplasia which is in Phase 2/3. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. The company has license and collaboration agreements with the Alexion Pharma International Operations Unlimited Company, Leland Stanford Junior University and Leidos Biomedical Research, Inc., and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.

BridgeBio Pharma, Inc.

Jefferies analyst Andrew Tsai maintained a Buy rating on BridgeBio Pharma today and set a price target of $110.00. Tsai covers the Healthcare secto...

Jefferies Sticks to Their Buy Rating for BridgeBio Pharma (BBIO)

Wells Fargo analyst reiterated a Buy rating on BridgeBio Pharma today and set a price target of $102.00. In a report released today, Piper Sandler ...

Wells Fargo Keeps Their Buy Rating on BridgeBio Pharma (BBIO)

Piper Sandler analyst Biren Amin maintained a Buy rating on BridgeBio Pharma today and set a price target of $115.00. According to TipRanks, Amin i...

Piper Sandler Remains a Buy on BridgeBio Pharma (BBIO)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BridgeBio Pharma (BBIO) and Rocket Pharmaceuticals (...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BBIO	$79.86	-1.66%	3.09M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BBIO	$79.86	-1.7%	3.09M
3
4
5
6

BBIO

Get BridgeBio Pharma, Inc. Data in Excel

Get BridgeBio Pharma, Inc. Data in Excel